home / stock / nrbo / nrbo news

NRBO News and Press, NeuroBo Pharmaceuticals Inc. From 10/14/21

Stock Information
Company Name: NeuroBo Pharmaceuticals Inc.
Stock Symbol: NRBO
Market: NASDAQ
Website: neurobopharma.com
Menu
NRBO NRBO Quote NRBO Short NRBO News NRBO Articles NRBO Message Board
Get NRBO Alerts

News, Short Squeeze, Breakout and More Instantly...
NRBO - Accelerating R&D Activities in Breast Cancer Therapy Market Fueling Optimism for Development of Advanced Treatments

Palm Beach, FL – October 14, 2021 – FinancialNewsMedia.com News Commentary – The breast cancer drugs market, which has been steadily growing over the past few years, is projected to continue this trend for the next several years. The breast cancer drugs mark...
NRBO - "The Buzz" Show: NeuroBo Pharmaceuticals (NASDAQ: NRBO) Independent Data Safety Committee

FinancialBuzz.com’s latest The Buzz Show: Featuring Our Corporate News Recap on “NeuroBo Pharmaceuticals, Inc. Announces Positive Recommendation from Independent Data Safety Monitoring Committee” NeuroBo Pharmaceuticals, Inc. (NASDAQ: NRBO) c...

NRBO - STAB, RLX and GWH among mid-day movers

Gainers: Jasper (NASDAQ:JSPR) +127%. Waitr Holdings (NASDAQ:WTRH) +55%. Clarus Therapeutics Holdings (NASDAQ:CRXT) +46%. Sono-Tek (NASDAQ:SOTK) +26%. Paltalk (NASDAQ:PALT) +21%. Statera Biopharma (NASDAQ:STAB) +20%. SMART Global Holdings (NASDAQ:SGH) +15%. NeuroBo Pharmaceuticals (NASDAQ:NRBO...

NRBO - CLLS, BBIG and GNLN among pre market gainers

NeuroBo Pharmaceuticals (NASDAQ:NRBO) +23% announces positive recommendation from independent data safety monitoring committee of phase 2/3 clinical trial of ANA001 in hospitalized patients with moderate to severe COVID-19 Jasper Therapeutics (NASDAQ:JSPR) +22% after bullish ca...
NRBO - NeuroBo Pharmaceuticals Announces Positive Recommendation from Independent Data Safety Monitoring Committee of Phase 2/3 Clinical Trial of ANA001 in Hospitalized Patients with Moderate to Severe COVID-19

NeuroBo Pharmaceuticals Announces Positive Recommendation from Independent Data Safety Monitoring Committee of Phase 2/3 Clinical Trial of ANA001 in Hospitalized Patients with Moderate to Severe COVID-19 Committee Advises Continuation of Trial Without Modification PR Newswir...

NRBO - NeuroBo Pharmaceuticals Closes $14 Million Registered Direct Offering

NeuroBo Pharmaceuticals Closes $14 Million Registered Direct Offering PR Newswire BOSTON , Oct. 5, 2021 /PRNewswire/ -- NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO), a clinical-stage biotechnology company focused on developing and commercializing multimodal, ...

NRBO - ADVM, SELB and OSUR among pre market gainers

Xenon Pharmaceuticals XENE +90% on positive XEN1101 data in mid-stage focal epilepsy study Elmira Savings Bank ESBK +66% Community Bank System to buy Elmira Savings Bank in $82.8M all cash deal OpGen OPGN +30% after announcing preliminary Q3 revenue ahead of expe...
NRBO - Progenity, Biomerica leads healthcare gainers; Omeros, Adagio Therapeutics among major losers

Gainers: Progenity (NASDAQ:PROG) +29%, Biomerica (NASDAQ:BMRA) +28%, Atea Pharmaceuticals (NASDAQ:AVIR) +19%, Silverback Therapeutics (NASDAQ:SBTX) +13%, Codexis (NASDAQ:CDXS) +12%. Losers: Omeros (NASDAQ:OMER) -41%, Adagio Therapeut...

NRBO - Novavax, Vir Biotechnology, Spire Global among premarket losers' pack

Tarena International (NASDAQ:TEDU) -20% after delivers notice of intent to terminate merger agreement due to breach by parent and merger sub Spire Global (NYSE:SPIR) -19%. IronNet (NYSE:IRNT) -14%. Vir Biotechnology (NASDAQ:VIR) -13%. Superior Drilling Products (NYSE:SDPI) -12%. Aer...

NRBO - NeuroBo Pharmaceuticals Announces $14 Million Registered Direct Offering

NeuroBo Pharmaceuticals Announces $14 Million Registered Direct Offering PR Newswire BOSTON , Oct. 1, 2021 /PRNewswire/ -- NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO), a clinical-stage biotechnology company focused on developing and commercializing multimod...
Previous 10 Next 10